Therapeutic Activity of Medroxyprogesterone Acetate in Metastatic Breast Cancer: A Correlation Between Estrogen Receptors and Various Dosages
It has been known for a relatively long time that progestogens, and especially medroxyprogesterone acetate (MPA), induce objective regression of the neoplasia in women with metastatic breast cancer. Some authors have recently reported [1, 7–9] that the response to MPA may be increased by employing high daily dosages. On this basis, we tested different dosages of MPA in patients who had become resistant to combined chemotherapy. Furthermore, we correlated the response of the patient with estrogen receptor status of the tumor.
KeywordsMetastatic Breast Cancer Objective Response Estrogen Receptor Status Medroxyprogesterone Acetate High Daily Dosage
Unable to display preview. Download preview PDF.
- 5.Di Fronzo G, Bertuzzi A, Ronchi E (1968) An improved criterion for the evaluation of estrogen receptor binding data in human breast cancer. Tumori 64: 259–266Google Scholar
- 8.Pannuti F, Martoni A, Di Marco AR, Piana E, Saccani F, Becchi G, Mattioli G, Barbanti F, Marra GA, Persiani W, Cacciari L, Spagnuolo F, Polenzana D, Rocchetta G (1979) Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate ( MPA) in the treatment of metastatic breast cancer. J Cancer 15: 593–601Google Scholar
- 9.Robustelli Della Cuna G, Calciati A, Bernando Strada MR, Bumma C, Campio L (1978) High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a due response evolution. Tumori 64: 143–150Google Scholar